INmune Bio Q3 net loss narrows 27% to $4.72 million
INMB•INmune Bio’s third-quarter 2026 net loss narrowed 27% year over year to $4.72 million. Cash was $16.33 million at September 30, and management expects resources to fund operations through the third quarter of 2027.
1. Quarterly results and cash
INmune Bio reported a third-quarter 2026 net loss of $4.72 million, down 27% year over year. Research and development expenses fell 35% to $3.16 million. Cash totaled $16.33 million at September 30, 2026, and management expects resources to fund operations through the third quarter of 2027.
2. Ebstrocel filing plans
The company targets early February 2027 for a complete UK marketing application for Ebstrocel, with potential approval in mid-2027 subject to regulatory review. A US biologics license application submission is targeted for mid-2027, subject to FDA feedback.
